A Multicentre, Randomized, Double-blinded, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 as Booster Vaccination in Adults 18 Years of Age or Older
Latest Information Update: 04 Oct 2023
At a glance
- Drugs LYB 001 (Primary)
- Indications COVID 2019 infections
- Focus Registrational; Therapeutic Use
- Sponsors Guangzhou Patronus Biotech
Most Recent Events
- 24 Sep 2023 Status changed from active, no longer recruiting to discontinued.
- 18 Jan 2023 New trial record